ONL-1204 is under clinical development by ONL Therapeutics and currently in Phase I for Geographic Atrophy. According to GlobalData, Phase I drugs for Geographic Atrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ONL-1204 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONL-1204 overview
ONL-1204 is under development for the treatment of retinal detachment, retinitis pigmentosa, non-infectious uveitis, open angle glaucoma, geographic atrophy, chronic glaucoma, dry and wet age-related macular degeneration. The drug candidate is administered through intravitreal route. It is a small molecule peptide analog of Met12 that acts by targeting the Fas receptor. It was also under development for
ONL Therapeutics overview
ONL Therapeutics is a biopharmaceutical company which is focused on protecting and improving the vision of patients with a range of retinal disease and conditions.? ONL Therapeutics is headquartered in Ann Arbor, Michigan, the US.
For a complete picture of ONL-1204’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
